A study published in Science reveals that SPC3649 successfully inhibits miR-122, a microRNA important for hepatitis C viral replication, significantly reducing the virus in the bloodstream and liver of chimpanzees chronically infected with HCV. The therapy's unique mechanism of action sets it apart from direct antiviral treatments.
The American Society of Hematology recognizes outstanding abstract presenters with the 2009 Merit Award, offering $500 honorariums to the best trainees in hemostasis and thrombosis. The winners include Kimberly Fan, Kyle Eash, Hélène Moniz, An De Weer, Suparna Nanua, MD, PhD, Jian Xu, PhD, and Rudy Fuentes.
Researchers have identified a microRNA (miR-2861) that regulates bone formation, and its mutation is linked to primary osteoporosis. In addition, studies on Lyme disease transmission revealed a biphasic mode of dissemination by Borrelia burgdorferi microbes within ticks.
A new cause of osteoporosis has been identified: a mutation in the miR-2861 precursor that blocks expression of this crucial microRNA. This microRNA promotes bone formation and its absence is linked to primary osteoporosis in humans.
Researchers identified microRNA-mediated suppression of tumor metastasis in breast cancer, highlighting three key miR-31 targets. These targets regulate metastatic colonization, a critical step in the metastasis process.
Researchers found that primary lung cancer shifts to metastatic disease by suppressing microRNA-200, a family of small molecules that normally locks the tumor in a noninvasive state. Protecting miR-200 from blockade completely prevented metastasis in mice.
Researchers at UCLA have confirmed the effectiveness of measuring microRNAs in saliva to detect oral squamous cell carcinoma. The study identifies two specific microRNAs, miR-125a and miR-200a, that are present at significantly different levels in the saliva of individuals with oral cancer.
Researchers identified 50 microRNAs in saliva that could help detect oral cancer, including miR-125a and miR-200a. The findings suggest a major step forward in early oral cancer detection.
Researchers at LSUHSC have identified miR-27b as a major player in the development of invasive breast cancer, found to stimulate cell growth and invasion. Meanwhile, ST14 gene suppresses tumor cell growth and may serve as an early detection marker for breast cancer.
A study found that miR-143 and miR-145 regulate the contractile nature of vascular smooth muscle cells, with their absence leading to increased tissue matrix production and signs of blood vessel disease. The findings suggest these microRNAs could serve as therapeutic targets for enhancing blood vessel repair.
Researchers identified miR-143 and miR-145 as key regulators of VSMC contractility and blood pressure. The study found that mice lacking these microRNAs had reduced contractile VSMCs and increased tissue matrix-producing cells, leading to signs of blood vessel disease.
Researchers at Stanford University School of Medicine have discovered a common molecular pathway used by breast cancer stem cells and normal breast stem cells when reproducing. Increasing the levels of miR-200c suppresses their ability to divide and reproduce.
Researchers at Ohio State University Comprehensive Cancer Center identified a molecule, miR-21, playing an early and important role in the development of nonsmoking lung cancer. The study found that miR-21 levels were high in both early and late-stage tumors, suggesting it happens early in cancer development.
Dr. Kai Fu receives $300K Clinical Investigator Career Development Award for mantle cell lymphoma research, focusing on miR-17~92 expression and its correlation with patient survival. The funding aims to support a pre-clinical study to determine the effectiveness of suppressing miR-17~92 in improving chemotherapy outcomes.
Researchers have discovered that two microRNAs, miR-143 and miR-145, control the differentiation and growth of vascular smooth muscle cells. These findings suggest that targeting these microRNAs may be a potential treatment for diseases such as atherosclerosis and Alzheimer's disease.
Researchers at Gladstone Institute discovered a key switch, microRNA-145 (miR-145), to turn stem cells into muscle cells that reside in blood vessel walls. This finding suggests restoring miR-145 activity could prevent artery narrowing and vessel disease.
A 16-nation research project is surveying the Mid-Atlantic Ridge for biodiversity, discovering potential new species and shedding light on deep-sea communities. The NOAA-led expedition aims to understand the ecosystem's structure and how it interacts with human activities.
Researchers have discovered that anti-inflammatory drugs used to treat arthritis can shrink lymphoma tumors in mice. The study strengthens evidence for a link between inflammation and cancer, suggesting a new way to curb the malignancy of this type of lymphoma.
Researchers at Whitehead Institute for Biomedical Research discovered a microRNA, miR-31, that inversely correlates with metastasis in breast cancer. Increasing miR-31 levels can help predict patient prognoses and potentially aid in the development of targeted therapies.
Researchers discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression. The study employed a novel strategy to treat hepatocellular (liver) cancer, using microRNAs (miRNA) gene delivery via a recombinant adeno-associated virus (AAV).
A study by Ueli Schibler's team reveals that a specific microRNA called miR-122 plays a crucial role in regulating the expression of circadian genes in liver cells. The discovery sheds light on the molecular mechanisms controlling the internal clock and its potential connection to hepatitis C virus replication.
The study found that miR-196a promotes the metastasis of tumors by activating oncogenic pathways, leading to increased lung metastases in animal models. Additionally, high levels of miR-196a were associated with poor patient survival in pancreatic cancer patients.
Researchers at Northwestern University have identified a snippet of RNA called miR-7 that helps maintain uniformity in individuals. The study found that miR-7 is critical to the molecular network regulating uniformity, which can help regulate cancer cells' behavior.
A new mouse model has been developed to understand the cause of progressive hearing loss, opening up avenues for treatment. The study found that a genetic mutation in microRNA seed region influences sensory hair cell production, leading to impaired hearing.
A study found that microRNA miR-504 regulates the expression of the dopamine D1 receptor gene, increasing the risk of nicotine dependence. The research suggests a potential link between smoking risk genes and neurobiology of addiction.
A study found a microRNA gene, miR-96, associated with progressive hearing loss in humans and mice. The mutation disrupts the development of sensory hair cells, leading to dramatic loss of hearing.
A new study found that boosting miR-29b levels in acute myeloid leukemia cells reverses gene changes, enabling the cells to differentiate and mature. This process could lead to a drop in global DNA methylation and reactivation of tumor suppressor genes, offering a potential treatment for AML.
Researchers have identified genetic markers associated with aggressive head and neck cancer, specifically miR-205 and let-7d. These microRNA levels can predict poor survival outcomes and may lead to targeted treatment options.
A new microRNA-based diagnostic test has been shown to identify squamous lung cancer with high accuracy, offering improved treatment options for patients. The test's 96% sensitivity and 90% specificity make it a promising tool in the fight against this aggressive form of cancer.
Researchers have discovered that microRNAs dampen target gene expression in specific cells by working in concert with other regulatory processes. Key muscle-regulatory miRNAs, such as miR-1 and miR-133, function to mediate actin organization in developing muscles.
Dr Catherine Jopling has received a prestigious David Phillips fellowship to investigate the molecular biology of hepatitis C virus. The £1m funding will support her work on miR-122, a specialized liver microRNA that interacts with HCV in an unusual way.
A new study identifies miR-23 as a microRNA that regulates myelin formation and maintenance. By turning down lamin gene expression, miR-23 prevents demyelination due to lamin overexpression, offering a potential treatment for demyelinating illnesses.
A study by Ohio State University researchers found that the molecule miR-29 is essential for muscle repair and maturation, but its absence is linked to rhabdomyosarcoma cancer. Raising miR-29 levels in cancer cells slowed tumor growth and induced maturity.
Scientists have developed a new approach to harness the power of microRNAs (miRNAs) as natural gene repressors for therapeutic purposes. By engineering mouse bone marrow cells to express genes only when miR-181a is downregulated, they were able to create immune cells that could target and destroy cancer cells.
Researchers have developed a new approach to modulate gene expression using miRNA natural gene repressors for therapeutic purposes, effectively treating cancer in mice. Additionally, the study has provided insight into the molecular mechanisms controlling epithelial fluid and HCO3– secretion, which may help understand cystic fibrosis.
Researchers have identified a single microRNA, miR-138, critical to the development of heart chambers in zebrafish. This discovery may provide new approaches for treating congenital heart defects. The study showed that miR-138 regulates numerous gene functions and is required during a specific developmental window.
Researchers identify a small molecule that blocks miR-21, a key player in brain and various types of cancer. The discovery offers new hope for developing targeted cancer therapies with fewer side effects.
Researchers have developed a computer program that will help astronauts manage psychosocial challenges, including depression and interpersonal conflicts. The Virtual Space Station is being tested with veteran astronauts, providing private access to treatments even when they're far from Earth.
Researchers at UT Southwestern Medical Center found that miR-126 is essential for creating new vessels in developing embryos and repair of injured blood vessels. However, its role in maintaining established vascular systems is unclear.
Researchers found that microRNA miR-126 regulates vascular development, structure, migration, proliferation and survival of endothelial cells. The study provides clues to potential therapeutic targets for diseases impacted by the vascular system.
A new study found that microRNA may influence the development of alcohol tolerance by regulating gene expression in brain cells. MicroRNA-9 was shown to block the expression of certain BK channel variants, which exhibited high alcohol sensitivity and low tolerance.
Researchers at Tufts University have found that Smad proteins control the processing of a subset of microRNA, including miR-21. This discovery reveals a new role of Smad proteins in regulating microRNA processing, which is a contributing factor in cardiovascular disorders and cancer.
Researchers found that restoring two small molecules in human chronic lymphocytic leukemia cells can block tumor growth and affect 70 genes involved in critical functions. These findings suggest a possible new treatment strategy for CLL.
Researchers found that microRNA miR-200 is a consistent marker of cancer cells expressing E-cadherin but lacking Vimentin. Altering miR-200 levels induced changes consistent with either inducing EMT or the reverse process.
Researchers have identified a master regulator of EMT that consists of a specific group of microRNAs called miR-200. Introducing miR-200 into late cancer cells may provide a new form of treatment by preventing cells from going through EMT and becoming more invasive.
A study published in Nature reveals that the protein REST maintains self-renewal and pluripotency in embryonic stem cells by suppressing a specific microRNA called miR-21. This discovery has implications for regenerative medicine and treating diseases, including pediatric brain cancer.
Research reveals that microRNA depletion is necessary for tissue regeneration and that manipulating certain microRNA levels can enhance regenerative success in zebrafish. By tweaking the FGF signaling pathway, scientists were able to increase or decrease specific microRNA levels, resulting in improved or inhibited fin regeneration.
Biologists at Duke University Medical Center have discovered microRNAs that control the regeneration of zebrafish fins. The study found that reducing levels of one microRNA, miR-133, speeds up fin regrowth, while increasing it slows it down. This discovery could lead to new ways to stimulate human tissue regeneration.
Researchers found a link between low microRNA levels and high gene activity in AML, suggesting new therapeutic targets. The study identified two genes in the Hox family that are over-active in leukemia cells, providing new insights into AML treatment.
Researchers at Gladstone Institutes have identified two microRNAs, miR-1 and miR-133, which play a crucial role in controlling the differentiation of pluripotent embryonic stem cells into cardiac muscle. These findings provide insight into fine-tuning cellular processes and may lead to new treatments for heart-related diseases.
Researchers are studying the effects of over- or underexpression of specific miRNAs on disease development and inhibition. For instance, scientists identified miR-373 and miR-520c, which promote tumor metastasis.
A study found that microRNA expression patterns are differentially expressed in colon tumor tissues, with certain miRNAs associated with poor survival and treatment outcomes. The researchers identified miR-21 as a potential diagnostic biomarker for colon adenocarcinomas and survival prognosis.
Two microRNAs, miR-373 and miR-520c, have been identified as promoting the spread of tumor cells. The study found that miR-373 is a potential biomarker for metastatic breast cancer and may be used to develop new treatments.
A study found that two microRNAs, miR-191 and miR-199a, are associated with patient survival in high-risk acute-leukemia patients. These molecules may serve as targets for future therapies, offering hope for patients with limited treatment options.
A study by Memorial Sloan-Kettering Cancer Center identifies a group of microRNA molecules that control genes causing breast cancer metastasis. The loss of these microRNAs allows cancer cells to migrate and grow more rapidly, leading to increased risk of lung and bone metastasis.
Research reveals antisense transcription of the Hox miRNA locus generates a novel miRNA precursor, mir-iab-8, which represses Hox gene targets, resulting in homeotic phenotypes. Additional antisense miRNAs identified in Drosophila and mammals may contribute to diversification of miRNA function.
Researchers have found that the Myc protein can stop the production of at least 13 microRNAs, which help control gene expression. Re-introducing repressed miRNAs into cancer cells suppressed tumor growth in mice, raising hopes for a novel therapy approach.
A research team has discovered that the Myc protein can suppress the production of at least 13 microRNAs in cancer cells. Reintroducing these repressed miRNAs into Myc-containing cancer cells suppressed tumor growth in mice, suggesting a potential gene therapy approach for certain cancers.
A new study reveals microRNAs can directly control a protein's function, preventing immature blood cells from maturing and contributing to the development of blast-crisis CML. Altering microRNA levels may represent a potential therapeutic strategy for CML patients who don't respond to targeted agents.
Researchers at UC Davis identified a cellular pathway involving microRNA miR-125b that contributes to the progression of prostate cancer. The discovery provides a potential target for reducing cancer deaths among American men.